{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:07:23Z","timestamp":1781003243851,"version":"3.54.1"},"reference-count":51,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravitreal injections (IVI\u200as) have gained increased popularity in the past decades and are used to treat a multitude of ailments. In 2010, the total number of IVI\u200as surpassed the number of cataract surgeries performed, making it the most common procedure in ophthalmology. As the number of injections increases, so does the number of injected-related complications. While complications in the posterior segment, such as retinal detachment or endophthalmitis, are detrimental to visual function and have therefore been well documented, IVI\u200as can also lead to complications in the anterior segment. These include hyphema, inflammation of the sterile anterior segment (incidence rate of 0.05 to 1.1% depending on the drug), implant migration with corneal decompensation (incidence rate of 0.43%), iatrogenic lens damage (incidence rate of 0.07%), accelerated cataract formation (up to 50% for steroids and 10.9% for anti-VEGF), and an increased complication rate during subsequent cataract\n          surgery (up to 4% per IVI). Most of these complications occur immediately and have a good prognosis if treated correctly. However, the increased risk of complications during subsequent surgery demonstrates that IVI\u200as can also have long-term complications, a topic that needs to be explored further in future research projects.<\/jats:p>","DOI":"10.1055\/a-2349-2224","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T22:30:30Z","timestamp":1723761030000},"page":"917-922","source":"Crossref","is-referenced-by-count":4,"title":["Anterior Segment Complications Following Intravitreal Injection"],"prefix":"10.1055","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-4522","authenticated-orcid":false,"given":"Lars H. B.","family":"Mackenbrock","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6927-5251","authenticated-orcid":false,"given":"Gerd U.","family":"Auffarth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-3423","authenticated-orcid":false,"given":"Tadas","family":"Naujokaitis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-9875","authenticated-orcid":false,"given":"Lucy J.","family":"Kessler","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6237-7773","authenticated-orcid":false,"given":"Ramin","family":"Khoramnia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/IAE.0b013e3181a94f01","article-title":"Intravitreal injection of therapeutic agents","volume":"29","author":"G A Peyman","year":"2009","journal-title":"Retina"},{"key":"ref2","first-page":"62","article-title":"IVT injections: health policy implications","volume":"21","author":"G A Williams","year":"2014","journal-title":"Rev Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","article-title":"Complications of intravitreal injections","volume":"21","author":"K M Sampat","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5301\/ejo.5000241","article-title":"Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab\u2013triamcinolone acetate combination","volume":"23","author":"Z Alkin","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3109\/02713683.2014.888452","article-title":"Short-term effects of intravitreal bevacizumab on cornea and anterior chamber","volume":"39","author":"M G\u00fcler","year":"2014","journal-title":"Curr Eye Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/15569527.2019.1616749","article-title":"Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure","volume":"38","author":"G D Arslan","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12886-018-0905-0","article-title":"Effect of dexamethasone intravitreal implant (Ozurdex\u00ae) on corneal endothelium in retinal vein occlusion patients: Corneal endothelium after dexamethasone implant injection","volume":"18","author":"H A G\u00fcler","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/icu.0000000000000154","article-title":"Ocular inflammation associated with antivascular endothelial growth factor treatment","volume":"26","author":"H F Fine","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/01.iae.0000234629.22614.cd","article-title":"Case of anterior uveitis after intravitreal injection of bevacizumab","volume":"26","author":"D J Pieramici","year":"2006","journal-title":"Retina"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12348-023-00369-8","article-title":"Gains in the current understanding of managing neovascular AMD with brolucizumab","volume":"13","author":"B Bodaghi","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00417-021-05518-0","article-title":"Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD","volume":"260","author":"R Khoramnia","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1055\/a-1675-2829","article-title":"[Bilateral Vasculitis after Single Intravitreal Brolucizumab Injection]","volume":"239","author":"L J Kessler","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00347-021-01330-7","article-title":"[Bilateral vasculitis following intravitreal brolucizumab injection]","volume":"119","author":"L J Kessler","year":"2022","journal-title":"Ophthalmologe"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/iae.0000000000000398","article-title":"Frequency and characteristics of intraocular inflammation after aflibercept injection","volume":"35","author":"H F Fine","year":"2015","journal-title":"Retina"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ophtha.2008.05.007","article-title":"Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration","volume":"115","author":"S S Wickremasinghe","year":"2008","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajo.2014.06.019","article-title":"Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes","volume":"158","author":"R A Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"D M Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"P J Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"928123","DOI":"10.1155\/2012\/928123","article-title":"Sterile endophthalmitis after intravitreal injections","volume":"2012","author":"J Marticorena","year":"2012","journal-title":"Mediators Inflamm"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jconrel.2008.02.010","article-title":"Preparing polymer-based sustained-release systems without exposing proteins to water-oil or water-air interfaces and cross-linking reagents","volume":"128","author":"T Jin","year":"2008","journal-title":"J Control Release"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00003226-200405000-00016","article-title":"Pseudohypopyon following intravitreal triamcinolone acetonide injection","volume":"23","author":"M C Sharma","year":"2004","journal-title":"Cornea"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/jop.2023.0027","article-title":"Functional and Morphological Responses to Fluocinolone Acetonide 0.19\u2009mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve","volume":"39","author":"L J Kessler","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/bjo-2022-321415","article-title":"Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study","volume":"107","author":"R Khoramnia","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/pharmaceutics14040688","article-title":"Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19\u2009mg Fluocinolone Acetonide Implant in Uveitic Macular Edema","volume":"14","author":"L J Kessler","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/jcm10173966","article-title":"Intravitreal 0.19\u2009mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis","volume":"10","author":"M Hikal","year":"2021","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211014728","article-title":"The impact of vitrectomy on outcomes achieved with 0.19\u2009mg fluocinolone acetonide implant in patients with diabetic macular edema","author":"A J Augustin","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12348-020-00225-z","article-title":"Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye \u2013 evaluating the 0.2\u2009\u00b5g\/day fluocinolone acetonide intravitreal implant (ILUVIEN\u00ae)","volume":"10","author":"B Bodaghi","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1120672119834474","article-title":"Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN\u00ae (0.19\u2009mg fluocinolone acetonide implant)","volume":"30","author":"A J Augustin","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12348-019-0168-9","article-title":"Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema","volume":"9","author":"L F Weber","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00417-017-3705-y","article-title":"The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex\u00ae)","volume":"255","author":"H Kang","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1007\/s10792-023-02838-4","article-title":"Anterior segment complications after dexamethasone implantations: real world data","volume":"43","author":"Y Ayaz","year":"2023","journal-title":"Int Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.18240\/ijo.2020.10.16","article-title":"Complications of dexamethasone implants: risk factors, prevention, and clinical management","volume":"13","author":"N Celik","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.5301\/ejo.5000715","article-title":"Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex\u00ae) through basal iridectomy (Ando) in a pseudophakic patient","volume":"26","author":"A Stepanov","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/icu.0000000000000365","article-title":"Anterior segment migration of dexamethasone implant: risk factors, complications, and management","volume":"28","author":"E Rahimy","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00347-023-01975-6","article-title":"[Cataract due to iatrogenic lens trauma during an intravitreal injection-imaging using (intraoperative) optical coherence tomography]","volume":"121","author":"L Britz","year":"2024","journal-title":"Ophthalmologie"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00347-024-01997-8","article-title":"[Lens injury as a complication of intravitreal medication injection]","volume":"121","author":"C R Clemens","year":"2024","journal-title":"Ophthalmologie"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.12998\/wjcc.v7.i22.3784","article-title":"Iatrogenic crystalline lens injury during intravitreal injection of triamcinolone acetonide: A report of two cases","volume":"7","author":"J Su","year":"2019","journal-title":"World J Clin Cases"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ajoc.2016.08.001","article-title":"Ozurdex completely located inside a crystallized lens \u2013 Results of 14 months","volume":"4","author":"B Baskan","year":"2016","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8630504","DOI":"10.1155\/2019\/8630504","article-title":"Accidental Intralenticular Injection of Ozurdex\u00ae for Branch Retinal Vein Occlusion: Intact Posterior Capsule and Resolution of Macular Edema","volume":"2019","author":"A Kurt","year":"2019","journal-title":"Case Rep Ophthalmol Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.5301\/ejo.5000436","article-title":"inadvertent dexamethasone implant injection into the lens body management","volume":"24","author":"A Berarducci","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1097\/ms9.0000000000000345","article-title":"Dropped nucleus postintravitreal injection with intact anterior capsule: a case report","volume":"85","author":"M M Al-Latayfeh","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jcrs.2009.05.050","article-title":"Management of cataract caused by inadvertent capsule penetration during intravitreal injection of ranibizumab","volume":"35","author":"M U Saeed","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/diagnostics12102406","article-title":"Automatic Quantitative Assessment of Lens Opacities Using Two Anterior Segment Imaging Techniques: Correlation with Functional and Surgical Metrics","volume":"12","author":"L HB Mackenbrock","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/a-2003-2369","article-title":"Cataract Classification Systems: A Review","volume":"241","author":"L HB Mackenbrock","year":"2024","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2147\/opth.S103443","article-title":"Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells","volume":"10","author":"J H Jun","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ajo.2005.01.022","article-title":"Cataract progression after intravitreal triamcinolone injection","volume":"139","author":"O Ceki\u00e7","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.ophtha.2016.02.014","article-title":"Previous Intravitreal Therapy Is Associated with Increased Risk of Posterior Capsule Rupture during Cataract Surgery","volume":"123","author":"A Y Lee","year":"2016","journal-title":"Ophthalmology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ajo.2017.02.006","article-title":"Risk of Posterior Capsule Rupture During Cataract Surgery in Eyes With Previous Intravitreal Injections","volume":"177","author":"Z Shalchi","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/aos.15089","article-title":"Previous intravitreal injection as a risk factor of posterior capsule rupture in cataract surgery: a systematic review and meta-analysis","volume":"100","author":"J Bjerager","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/bjophthalmol-2020-318645","article-title":"Risk model for intraoperative complication during cataract surgery based on data from 900 000 eyes: previous intravitreal injection is a risk factor","volume":"106","author":"P H\u00e5rd Af Segerstad","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/02713683.2020.1795884","article-title":"Posterior Capsule Rupture during Cataract Surgery in Eyes Receiving Intravitreal anti-VEGF Injections","volume":"46","author":"D C Miller","year":"2021","journal-title":"Curr Eye Res"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2349-2224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:14:11Z","timestamp":1730805251000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2349-2224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":51,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2349-2224","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}